Trial · NCT05247489
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib 1.5% Cream BID | 1 | 20 | 1 |
| other | Acne | Skin and subcutaneous tissue disorders | Ruxolitinib 1.5% Cream BID + NB-UVB | 1 | 35 | 1 |
| other | Acne | Skin and subcutaneous tissue disorders | Total | 2 | 55 | 2 |
| other | Animal bite | Injury, poisoning and procedural complications | Ruxolitinib 1.5% Cream BID | 1 | 20 | 1 |
| other | Animal bite | Injury, poisoning and procedural complications | Ruxolitinib 1.5% Cream BID + NB-UVB | 0 | 35 | 0 |
| other | Animal bite | Injury, poisoning and procedural complications | Total | 1 | 55 | 1 |
| other | Application site acne | General disorders | Ruxolitinib 1.5% Cream BID | 2 | 20 | 2 |
| other | Application site acne | General disorders | Ruxolitinib 1.5% Cream BID + NB-UVB | 4 | 35 | 4 |
| other | Application site acne | General disorders | Total | 6 | 55 | 6 |
| other | Bacterial vaginosis | Infections and infestations | Ruxolitinib 1.5% Cream BID | 1 | 20 | 1 |
| other | Bacterial vaginosis | Infections and infestations | Ruxolitinib 1.5% Cream BID + NB-UVB | 0 | 35 | 0 |
| other | Bacterial vaginosis | Infections and infestations | Total | 1 | 55 | 1 |
| other | Bronchitis | Infections and infestations | Ruxolitinib 1.5% Cream BID | 2 | 20 | 2 |
| other | Bronchitis | Infections and infestations | Ruxolitinib 1.5% Cream BID + NB-UVB | 0 | 35 | 0 |
| other | Bronchitis | Infections and infestations | Total | 2 | 55 | 2 |
| other | COVID-19 | Infections and infestations | Ruxolitinib 1.5% Cream BID | 1 | 20 | 1 |
| other | COVID-19 | Infections and infestations | Ruxolitinib 1.5% Cream BID + NB-UVB | 1 | 35 | 1 |
| other | COVID-19 | Infections and infestations | Total | 2 | 55 | 2 |
| other | Cataract | Eye disorders | Ruxolitinib 1.5% Cream BID | 1 | 20 | 1 |
| other | Cataract | Eye disorders | Ruxolitinib 1.5% Cream BID + NB-UVB | 1 | 35 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05247489/events